TFThomas D. Filardo

Thomas D. Filardo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas D. Filardo has a total of 109 co-authors. Here are the top co-authors by number of shared publications:

  • David E. Sugerman

    Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia

    4 shared publications
  • Tatiana M. Lanzieri

    Division of Viral Diseases National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention Atlanta Georgia USA

    3 shared publications
  • Adria D. Mathis

    Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia

    2 shared publications
  • Brian F. Borah

    Chicago Department of Public Health Disease Control and Emergency Prepardness Bureau Chicago, Illinois

    2 shared publications
  • Brian Wakeman

    Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia

    2 shared publications
  • Jessica Prince-Guerra

    Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia

    2 shared publications

Latest Publications

  • Sensitivity of Measles Real-time Reverse-transcription Polymerase Chain Reaction Testing During an Outbreak in Persons Without Rash

    by Kimberly Gressick, Stephanie Gretsch, Thomas D Filardo, Peter M DeJonge, Brian F Borah

    During the 2024 Chicago measles outbreak, 120 real-time reverse-transcription polymerase chain reaction tests were performed on 117 symptomatic persons with measles exposure, but without rash; test sensitivity was 78% (7 true positive). After an initial negative test, providers should maintain suspicion of measles and repeat testing as symptoms progress.

  • Seroprevalence of Measles, Mumps, Rubella, and Varicella-Zoster Virus Antibodies—United States, 2017–March 2020

    by Chelsea S Lutz, Patricia Castro-Roman, Mona Marin, Brian Wakeman, Stephen N Crooke, Elina El-Badry, Nicole A Escudero Gonzalez, Thomas D Filardo, Zhizhou Kuang, Daniel L Joo, et al.

    Background: The most recent assessment of antibodies against measles, mumps, rubella, and varicella-zoster viruses (MeV, MuV, RuV, VZV) in the United States was conducted in 2009–2010. Regular assessments are essential to measure the impact of immunization programs, identify immunity gaps, and inform vaccination strategies. We report updated estimates of national seroprevalence. Methods: We used a CDC-developed immunoglobulin G multiplex bead assay to quantitatively detect antibodies against MeV, MuV, RuV, and VZV among participants aged 6–59 years in the 2017–March 2020 National Health and Nutrition Examination Survey. We estimated seroprevalence overall and by sociodemographic characteristics and assessed independent predictors of seropositivity using logistic regression models with weighted procedures for complex survey design. Results: Overall seroprevalence was 95.2% (95% CI, 94.0%–96.3%) against MeV, 87.8% (95% CI, 86.5%–89.2%) against MuV, 95.6% (95% CI, 94.5%–96.5%) against RuV, and 97.2% (95% CI, 96.4%–98.0%) against VZV and remained high across advancing age groups. Younger age and non-Hispanic Black race and ethnicity were independent predictors for MeV, MuV, and RuV seropositivity; sex, birthplace, and health insurance status were independent predictors for seropositivity for at least one of the viruses. Conclusions: Nationally, seroprevalence for MeV, MuV, RuV, and VZV antibodies remains high among persons aged 6–59 years, and our findings indicate robust antibody responses are maintained decades after vaccination or natural infection. Maintaining high population immunity through vaccination is critical to prevent cases and outbreaks of all 4 vaccine-preventable diseases.

  • Effectiveness of Measles-Mumps-Rubella Vaccination Among Persons Residing in a Congregate Migrant Shelter During a Measles Outbreak: An Observational Cohort Study

    by Chelsea S Lutz, Thomas D Filardo, Peter M DeJonge, Stephanie Gretsch, Kimberly Gressick, David E Sugerman, Tatiana M Lanzieri, Jessica Leung, Kelley Raines, Ruth Link-Gelles, et al.

    Background: On 7 March 2024, the Chicago Department of Public Health was notified of a positive measles test in a resident of a shelter housing >2100 persons. We estimated the effectiveness of measles-mumps-rubella vaccine (MMR) administered during the outbreak to guide its use as an acute intervention. Methods: We used Pearson χ2 tests to compare unadjusted attack rates (ARs) by age group, number of days exposed, and sex. We estimated adjusted hazard ratios (aHRs) using time-dependent Cox proportional hazards regression models to assess the association between time-varying MMR dose status and the outcome of laboratory-confirmed measles; the final model was adjusted for time-varying exposure to measles virus and age group. We estimated risk-adjusted vaccine effectiveness (VE) as VE = (1 – aHR) × 100. Results: Measles was diagnosed in 52 of 2243 (2.3%) residents who resided in the shelter for ≥1 day during 22 February–4 April 2024. ARs were highest among children aged <6 months (57.1%) and 6–11 months (55.6%) and among residents who were exposed for 8–13 days (10.1%). ARs did not differ by sex. Estimated 1-dose VE was 70% (95% confidence interval [CI], 28%–88%) and estimated ≥2-dose VE was 72% (95% CI, 21%–90%). Conclusions: This study provided a unique opportunity to evaluate MMR VE in a contemporary outbreak setting with a high force of infection and could guide future responses in similar congregate settings. MMR was effective at preventing measles among shelter residents. Public health efforts that prioritize vaccinating persons without ≥2 MMR doses remain critical for limiting transmission.

  • Multiple Measles Transmission Events Associated With a Single Traveler Arriving in the United States, May 2025

    by Jennifer J Fowler, Amanda Metz, Meghan Barnes, Shannon L Gearhart, Thomas D Filardo, Brian Wakeman, Jessica Prince-Guerra, Heather Colley, Thuy Kim, Francis Chu, et al.

    Background: Travelers who fly on commercial aircraft while infectious with measles are reported to the US Centers for Disease Control and Prevention (CDC) by health departments. CDC contacts airlines to collect information on potentially exposed travelers. Traveler locating information is shared with health departments to facilitate aircraft contact investigations. In May 2025, CDC was notified of a traveler who flew from Europe to Colorado while infectious with measles, transited through Denver International Airport, then flew from Colorado to North Dakota. This report describes details of the subsequent contact investigations, environmental assessment, and laboratory testing results. Methods: CDC laboratories conducted testing on a majority of case samples. Data from the CDC laboratory, CDC's Port Health Activity Reporting System, and health department investigations were analyzed to describe the index case, contacts, test results, and travel details. Flight records and visual inspection were used to describe relative locations of index and secondary case-patients at Denver International Airport. Results: The index case was in an unvaccinated adult. Aircraft contact investigations identified 135 exposed domestic travelers. Fifteen secondary cases were identified among people exposed during the international (5) and domestic (3) flights and at the airport (7). Two tertiary case-patients were also identified. Five of the secondary case-patients had at least 1 documented prior measles vaccination. Conclusions: Measles transmission may occur during travel. Measles vaccination is recommended prior to international travel for all travelers aged 6 months or older. Travelers with fever and other overt signs of transmissible illness, such as coughing or malaise, should be strongly encouraged to delay travel while symptomatic.

  • Continued elimination of measles, rubella and congenital rubella syndrome in the United States, January 2022–June 2024

    by Thomas D. Filardo, Adria D. Mathis, Kelley Raines, Stephen N. Crooke, R. Suzanne Beard, Jessica Prince-Guerra, Paul A. Rota, David E. Sugerman

  • Open Access

    Epidemiology and Clinical Characteristics of Ocular Tuberculosis in the United States, 1993–2019

    by Thomas D Filardo, Aryn Andrzejewski, Michael Croix, Julie L Self, Henry S Fraimow, Sonal S Munsiff

    Data regarding ocular tuberculosis (OTB) in the United States have not been previously reported. We evaluated trends of OTB compared with other extrapulmonary TB (EPTB). We estimated the proportion of all EPTB cases (with or without concurrent pulmonary involvement) with OTB reported to the National Tuberculosis Surveillance System during 1993–2019. We compared demographics and clinical characteristics of people with OTB and other EPTB during 2010–2019. P values were calculated by chi-square test for categorical variables and Kruskal-Wallis for continuous variables. During 1993–2019, 1766 OTB cases were reported, representing 1.6% of 109 834 all EPTB cases: 200 (0.5% of 37 167) during 1993–1999, 395 (1.0% of 41 715) during 2000–2009, and 1171 (3.8% of 30 952) during 2010–2019. In contrast to persons with other EPTB, persons with OTB were older (median, 48 vs 44 years; P < .01), more likely to be US-born (35% vs 28%; P < .01), more likely to have diabetes (17% vs 13%; P < .01), and less likely to have HIV (1% vs 8%; P < .01). OTB was less likely to be laboratory confirmed (5% vs 75%; P < .01), but patients were more likely to be tested by interferon gamma release assay (IGRA; 84% vs 56%; P < .01) and to be IGRA positive (96% vs 80%; P < .01). Reported OTB increased during 1993–2019 despite decreasing TB, including EPTB; the largest increase occurred during 2010–2019. OTB was rarely laboratory confirmed and was primarily diagnosed in conjunction with IGRA results. More research is needed to understand the epidemiology of OTB to inform clinical and diagnostic practices.


  • Appropriateness of Immunoglobulin M Testing for Measles, Mumps, and Rubella

    by Thomas D. Filardo, Nina B. Masters, Jessica Leung, Sarah Baca, Heartley Egwuogu, Oscar Rincon Guevara, Julia Raykin, David E. Sugerman


  • Open Access

    Measles and Rubella Diagnostic and Classification Challenges in Near- and Post-Elimination Countries

    by Thomas D. Filardo, Stephen N. Crooke, Bettina Bankamp, Kelley Raines, Adria D. Mathis, Tatiana M. Lanzieri, R. Suzanne Beard, Ludmila Perelygina, David E. Sugerman, Paul A. Rota

    Measles and rubella are vaccine-preventable viral diseases and can be prevented by safe, highly effective vaccination with measles- and rubella-containing vaccines. Given the myriad causes of febrile exanthems, laboratory surveillance for both measles and rubella is important to document the incidence of these diseases and to track the progress and maintenance of elimination in near- and post-elimination settings. Diagnostic challenges can hinder effective surveillance and classification challenges can hinder efforts to demonstrate achievement or maintenance of elimination. In this report, we review diagnostic and classification challenges for measles and rubella in near- and post-elimination settings.


  • Open Access

    Incomplete tissue product tracing during an investigation of a tissue-derived tuberculosis outbreak

    by Kristen E. Marshall, Rebecca J. Free, Thomas D. Filardo, Noah G. Schwartz, Alfonso C. Hernandez-Romieu, Tyler C. Thacker, Kimberly A. Lehman, Pallavi Annambhotla, Peter B. Dupree, Janet Burton Glowicz, et al.


  • Open Access

    Mpox vaccine acceptability among people experiencing homelessness in San Francisco — October–November 2022

    by Thomas D. Filardo, Namrata Prasad, Caroline J. Waddell, Neela Persad, Gerald J. Pellegrini, Deborah Borne, Julia Janssen, Anamaría Bejarano, Grace E. Marx, Emily Mosites